Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinoma

…, G Balzano, P Passoni, A Rognone, C Fugazza… - Cancer, 2009 - Wiley Online Library
BACKGROUND: Radiologic assessment of tumor response in pancreatic cancer is complicated
by desmoplastic reactions within or around the tumor. The objective of this study was to …

[HTML][HTML] Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial

…, F Bergamo, E Franceschi, C Fugazza… - European Journal of …, 2013 - Elsevier
Background New strategies to prolong disease control warrant investigation in patients with
metastatic pancreatic adenocarcinoma. This open-label, randomised, multi-centre phase II …

[HTML][HTML] A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable …

…, P Passoni, C Pircher, M Chiaravalli, C Fugazza… - European Journal of …, 2018 - Elsevier
Background The current trial assessed whether the addition of cisplatin and capecitabine to
the nab-paclitaxel–gemcitabine backbone is feasible and active against borderline and …

A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or …

…, C Belli, M Ghidini, S Longoni, C Fugazza… - Cancer chemotherapy …, 2012 - Springer
Purpose PEFG regimen (P:cisplatin, E:epirubicin, F:5-fluorouracil, G:gemcitabine) significantly
prolonged progression-free (PFS) and overall survival (OS) of patients with advanced …

[HTML][HTML] Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable …

…, G Pepe, C Doglioni, C Fugazza… - British Journal of …, 2016 - nature.com
Background: Nab-paclitaxel–gemcitabine combination significantly improved overall
survival over gemcitabine in metastatic pancreatic adenocarcinoma. A phase 1b trial was …

Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial

…, C Milandri, P Saletti, A Rognone, C Fugazza… - Annals of surgical …, 2012 - Springer
Background Information from randomized trials on the role of combination chemotherapy in
the adjuvant treatment of pancreatic adenocarcinoma is limited. This randomized phase II …

XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer

…, M Ghidini, C Belli, S Longoni, C Fugazza… - Anticancer …, 2010 - ar.iiarjournals.org
Background: More than half of patients with pancreatic adenocarcinoma (PA) are candidates
for further treatment when they experience upfront treatment failure. Patients and Methods: …

Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial

S Cereda, M Reni, A Rognone, C Fugazza, M Ghidini… - Chemotherapy, 2011 - karger.com
Background: At the time of upfront treatment failure, over half of the patients with advanced
pancreatic cancer are candidates for further treatment. Methods: Patients with metastatic …

Maintenance sunitinib (MS) or observation (O) in metastatic pancreatic adenocarcinoma (MPA): Clinical and translational results of a phase II randomized trial …

…, F Bergamo, E Franceschi, B Rovati, C Fugazza… - 2012 - ascopubs.org
4017 Background: Combination chemotherapy (CT) prolonged progression-free survival at
6 months (PFS6) of patients (pts) with MPA from <20% with gemcitabine (GEM) to >50%. To …

Multidrug regimens for treatment of older patients with metastatic pancreatic cancer

…, U Peretti, E Mazza, MM Valente, C Fugazza… - Digestive and Liver …, 2021 - Elsevier
Background and Aims Older patients with metastatic pancreatic adenocarcinoma (MPDAC)
are under-represented in clinical trials. Methods Our single-center, retrospective study …